Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02159066
Title	LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
Acronym	LOGIC-2
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	melanoma
Therapies	Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib Binimetinib + Encorafenib + Infigratinib
Age Groups:	adult
Covered Countries	USA \| NLD \| ITA \| GBR \| ESP \| DEU \| CHE \| CAN \| AUS